RBC Capital Markets has raised its rating on Fisher & Paykel Healthcare, a New Zealand-based medical device maker, to “outperform” from its previous stance. The upgrade comes as the bank sees the company with significant room to expand within hospital settings, and it believes Fisher & Paykel could beat its own profit guidance for fiscal 2027.
Fisher & Paykel Healthcare is known for its respiratory care products, including high-flow therapy devices used in hospitals to help patients breathe more easily. These devices are widely used in intensive care units and general wards, and the company has built a strong reputation for quality and innovation.
Why the upgrade?
RBC’s analysts argue that while Fisher & Paykel already sells essential hospital equipment, its products are only lightly penetrated in many hospital departments. This “white space” represents a substantial growth opportunity. When a hospital adopts more of its high-flow therapy devices, that equipment tends to generate steady follow-on sales—consumables and accessories that are used regularly and need replacing.
The bank also points to the possibility that Fisher & Paykel could beat its fiscal 2027 profit guidance of NZ$525 million to NZ$565 million. That guidance, set by the company, reflects its own expectations for the year ending March 2027. An outperform rating from RBC suggests the bank expects the stock to do better than the broader market or its sector over the next 12 months or so.
This is not the first time RBC has been bullish on a company. Recently, the bank started coverage of Dell with an outperform rating, citing a massive AI server backlog. And it has kept Inditex at outperform despite rising transport costs. The bank’s positive stance on Fisher & Paykel fits a pattern of identifying companies with strong growth drivers.
What does this mean for investors?
For everyday investors, an upgrade from a major bank like RBC is a signal that professional analysts see more upside in the stock. But it’s important to remember that analyst ratings are opinions, not guarantees. The stock market can be unpredictable, and even well-researched calls can be wrong.
Still, the upgrade highlights a few key points. First, Fisher & Paykel operates in a sector—medical technology—that tends to be resilient even in economic downturns, because hospitals need these products regardless of the economy. Second, the company’s focus on hospital markets, rather than just home care, gives it a broad base of demand. Third, the potential to beat its own profit guidance suggests that the company’s management may be conservative in its forecasts, which could lead to positive surprises down the road.
Investors should also consider the broader context. The medical device industry has been through ups and downs, with some companies seeing slower growth after the pandemic boom. However, UBS recently noted that Thermo Fisher and Danaher are returning to steady growth, indicating that the sector may be stabilizing. Fisher & Paykel’s upgrade comes at a time when medtech is in focus.
Risks to consider
No investment is without risk. Fisher & Paykel faces competition from other medical device makers, and its growth depends on hospitals continuing to adopt its technology. Currency fluctuations can also affect its earnings, since it reports in New Zealand dollars but sells globally. And if hospital budgets tighten, spending on new equipment could slow.
That said, the company has a track record of innovation and a strong presence in key markets. Its high-flow therapy devices have become standard in many hospitals, and the recurring revenue from consumables provides a stable base.
What to watch next
Investors will be watching Fisher & Paykel’s upcoming earnings reports to see if the company maintains its momentum. Any updates on hospital adoption rates or new product launches could move the stock. Also, keep an eye on the broader medtech sector, as Japan's earnings season has tripped up some retailers and medtech firms, showing that even strong results can be met with market skepticism.
For those interested in the healthcare space, this upgrade is a reminder that medical technology companies can offer growth opportunities, but it's always wise to do your own research and consider how a stock fits into your overall portfolio.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always consult a qualified professional before making investment decisions.
